Immunitybio Company Insiders
| IBRX Stock | USD 3.16 0.08 2.60% |
Immunitybio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Immunitybio suggests that vertually all insiders are extremely bullish. Immunitybio employs about 672 people. The company is managed by 13 executives with a total tenure of roughly 1568 years, averaging almost 120.0 years of service per executive, having 51.69 employees per reported executive.
Immunitybio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-06-05 | Michael D Blaszyk | Acquired 71915 @ 2.75 | View | ||
| 2023-06-02 | John Owen Brennan | Acquired 25000 @ 2.83 | View |
Monitoring Immunitybio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Immunitybio |
Immunitybio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Immunitybio's future performance. Based on our forecasts, it is anticipated that Immunitybio will maintain a workforce of slightly above 670 employees by March 2025.Immunitybio Management Team Effectiveness
The company has return on total asset (ROA) of (0.5635) % which means that it has lost $0.5635 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.94 in 2025, whereas Return On Tangible Assets are likely to drop (1.44) in 2025. At this time, Immunitybio's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 254 M in 2025, whereas Total Current Assets are likely to drop slightly above 172.1 M in 2025.Common Stock Shares Outstanding is likely to drop to about 399.6 M in 2025. Net Loss is likely to rise to about (356.2 M) in 2025
Immunitybio Workforce Comparison
Immunitybio is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 4,857. Immunitybio retains roughly 672 in number of employees claiming about 14% of equities under Health Care industry.
Immunitybio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immunitybio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 1.0 | 1 | 1 | 110,020 | 110,020 |
| 2024-12-01 | 0.6667 | 6 | 9 | 117,271,171 | 126,294 |
| 2024-03-01 | 1.75 | 14 | 8 | 4,635,367 | 349,715 |
| 2023-12-01 | 1.0 | 5 | 5 | 85,910 | 113,517 |
| 2023-09-01 | 2.0 | 10 | 5 | 209,774,383 | 160,815 |
| 2023-06-01 | 15.0 | 15 | 1 | 1,074,523 | 21,030 |
| 2023-03-01 | 0.5 | 1 | 2 | 83,333 | 125,525 |
| 2022-12-01 | 0.75 | 3 | 4 | 10,003,138 | 20,491 |
| 2022-03-01 | 4.0 | 8 | 2 | 1,297,619 | 112,748 |
| 2021-12-01 | 4.0 | 4 | 1 | 82,263 | 17,242 |
| 2021-09-01 | 0.2857 | 2 | 7 | 16,218 | 90,799 |
| 2021-06-01 | 3.0 | 12 | 4 | 326,907 | 181,967 |
| 2021-03-01 | 0.8824 | 15 | 17 | 244,871,368 | 781,330 |
| 2020-12-01 | 0.3333 | 1 | 3 | 130,000 | 302,592 |
| 2020-09-01 | 0.2778 | 5 | 18 | 179,950 | 528,658 |
| 2020-06-01 | 0.7692 | 10 | 13 | 4,385,684 | 515,734 |
| 2020-03-01 | 0.5 | 1 | 2 | 15,000 | 21,132 |
| 2019-09-01 | 0.2 | 1 | 5 | 10,000 | 37,458 |
| 2019-03-01 | 1.0 | 2 | 2 | 19,440,750 | 19,440,750 |
| 2018-09-01 | 1.0 | 4 | 4 | 449,257 | 59,257 |
| 2018-06-01 | 0.1667 | 3 | 18 | 81,966 | 214,103 |
| 2018-03-01 | 0.5 | 1 | 2 | 15,000 | 19,500 |
| 2017-09-01 | 0.25 | 1 | 4 | 54,621 | 143,445 |
| 2017-06-01 | 0.6667 | 4 | 6 | 95,012 | 92,500 |
| 2017-03-01 | 0.5 | 1 | 2 | 5,000 | 6,983 |
| 2016-12-01 | 0.1429 | 1 | 7 | 5,000 | 490,604 |
| 2016-09-01 | 0.4286 | 3 | 7 | 5,808,476 | 438,689 |
| 2016-06-01 | 0.8 | 4 | 5 | 656,737 | 638,445 |
| 2016-03-01 | 1.0 | 5 | 5 | 243,439 | 239,439 |
| 2015-12-01 | 4.0 | 4 | 1 | 2,003,265 | 35,000 |
| 2015-09-01 | 0.25 | 6 | 24 | 3,060,900 | 23,349,504 |
Immunitybio Notable Stakeholders
An Immunitybio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immunitybio often face trade-offs trying to please all of them. Immunitybio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immunitybio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard Adcock | CEO President | Profile | |
| Jason JD | General Secretary | Profile | |
| Sandeep MD | Chief Officer | Profile | |
| Helen Luu | Chief Officer | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Jason Liljestrom | General Secretary | Profile | |
| Barry MD | Chief Director | Profile | |
| Hans MD | Chief Cellular | Profile | |
| FRCS FACS | Executive Officer | Profile | |
| Regan Lauer | Chief Officer | Profile | |
| David Sachs | Principal CFO | Profile | |
| RAC Dilon | Chief Officer | Profile | |
| Sarah Singleton | Chief Advocacy | Profile |
About Immunitybio Management Performance
The success or failure of an entity such as Immunitybio often depends on how effective the management is. Immunitybio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunitybio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunitybio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.38) | (1.44) | |
| Return On Capital Employed | (0.93) | (0.98) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | 0.89 | 0.94 |
Please note, the imprecision that can be found in Immunitybio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunitybio. Check Immunitybio's Beneish M Score to see the likelihood of Immunitybio's management manipulating its earnings.
Immunitybio Workforce Analysis
Traditionally, organizations such as Immunitybio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immunitybio within its industry.Immunitybio Manpower Efficiency
Return on Immunitybio Manpower
| Revenue Per Employee | 926 | |
| Revenue Per Executive | 47.8K | |
| Net Loss Per Employee | 867.9K | |
| Net Loss Per Executive | 44.9M | |
| Working Capital Per Employee | 350.9K | |
| Working Capital Per Executive | 18.1M |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.